Structure of Dabigatran etexilate CAS 211915-06-9

Dabigatran etexilate CAS 211915-06-9

/in , , /by

Identification
Properties
Safety Data
Specifications & Other Information
Links

Identification

CAS Number

211915-06-9

Name

Dabigatran etexilate

Synonyms

211915-06-9 [RN]
2E18WX195X
8028
BIBR-1048MS
Dabigatran etexilate [INN] [USAN] [Wiki]
Dabigatran etexilate
Ethyl N-[(2-{[(4-{N-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-2-pyridinyl-β-alaninate [ACD/IUPAC Name]
Ethyl-N-[(2-{[(4-{N-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-2-pyridinyl-β-alaninat [German] [ACD/IUPAC Name]
N-[(2-{[(4-{N-[(Hexyloxy)carbonyl]carbamimidoyl}phényl)amino]méthyl}-1-méthyl-1H-benzimidazol-5-yl)carbonyl]-N-2-pyridinyl-β-alaninate d’éthyle [French] [ACD/IUPAC Name]
Pradax [Trade name]
Pradaxa [Trade name]
Rendix [Trade name]
β-Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester [ACD/Index Name]
[211915-06-9]
1415506-16-9 [RN]
1610666-09-5 [RN]
3-[[[2-[[4-[(E)-amino-[hexoxy(oxo)methyl]iminomethyl]anilino]methyl]-1-methyl-5-benzimidazolyl]-oxomethyl]-(2-pyridinyl)amino]propanoic acid ethyl ester
3-[[[2-[[4-[(Z)-amino-[hexoxy(oxo)methyl]iminomethyl]anilino]methyl]-1-methyl-5-benzimidazolyl]-oxomethyl]-(2-pyridinyl)amino]propanoic acid ethyl ester
BIBR 1048
BIBR 1048|Pradaxa®
BIBR-1048 (Dabigatran)
Dabigatran Etexilate Mesylate [USAN]
Dabigatran?etexilate
ethyl (Z)-3-(2-(((4-(N’-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
Ethyl 3-(((2-(((4-((((hexyloxy)carbonyl)amino)iminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)(pyridin-2-yl) amino)propanoate
Ethyl 3-(((2-(((4-((((hexyloxy)carbonyl)amino)iminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)(pyridin-2-yl)amino)propanoate
ethyl 3-(1-{2-[({4-[(1E)-amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate
ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate
ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate
ethyl 3-(2-((4-(N-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate
ethyl 3-[[2-[[[4-(N’-hexoxycarbonylcarbamimidoyl)phenyl]amino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
ethyl 3-[[2-[[4-[(E)-N’-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
ethyl 3-[[2-[[4-[(Z)-N’-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
ethyl N-[(2-{[(4-{N’-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-β-alaninate
ethyl N-[(2-{[(4-{N-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-β-alaninate
MFCD16038312 [MDL number]
MFCD22422841 [MDL number]
N-[[2-[[[4-[[[(hexloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-?-alanine, ethyl ester
N-[2-[4-[N-(Hexyloxycarbonyl)amidino]phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcarbonyl]-N-(2-pyridyl)-β-alanine ethyl ester
N-[2-[4-[N-(Hexyloxycarbonyl)amidino]phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcarbonyl]-N-(2-pyridyl)-β-alanineethylester
Pradax; Rendix
Prazaxa
Prazaxa; BIBR 1048; BIBR-1048
Rabigatran etexilate
UNII:2E18WX195X
UNII-2E18WX195X

Molecular Structure

Structure of Dabigatran etexilate CAS 211915-06-9

Structure of Dabigatran etexilate CAS 211915-06-9

SMILES

CCCCCCOC(=O)/N=C(\c1ccc(cc1)NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c4ccccn4)/N

StdInChI

InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)

StdInChIKey

KSGXQBZTULBEEQ-UHFFFAOYSA-N

Molecular Formula

C34H41N7O5

Molecular Weight

627.74

Safety Data

WGK Germany

3

Specifications and Other Information of Our Dabigatran etexilate CAS 211915-06-9

Standard

Enterprise standard

GMP

LCFDA

Basic Patent Situation

US expiry date20180218
EU expiry date20230215
JP expiry date20240824

Package

According to customer requirements to packaging

Storage

Under the room temperature and away from light

Application

Used as the Anti-thrombotic

Links

This product is developed by our sub R&D company Caming Pharmaceutical Ltd, and please click the link below for details.
http://www.caming.com/dabigatran-etexilate-cas-211915-06-9/

This product is sold exclusively through our sales company Watson International Ltd, and please click the link below for details.
http://www.watson-int.com/dabigatran-etexilate-cas-211915-06-9/